A drug that is the focus of legal action by Silence Therapeutics PLC (LON:SLN) has been granted limited approval here in the UK.
Patisiran, a new-breed of RNAi medicine developed by American biotech Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), will join the Early Access to Medicines Scheme.
READ: Silence Therapeutics names experienced biotech boss as its new chief executive officer
This means Britons with a rare neuro-degenerative disease can receive the treatment before it gains EU marketing authorisation.
Patisiran is at the centre of a court case, set for trial in December, with Silence Therapeutics claiming it infringes intellectual property (IP) the UK life sciences group developed and owns.
“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said chief executive, Dr David Horn Solomon.